Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002952 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy and Interleukin-12 in Treating Patients With Metastatic Melanoma
A Phase 1 study of Melanoma (Skin), sponsored by University of Chicago.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT00002952 is a Phase 1 study of Melanoma (Skin) that has completed, run by University of Chicago. The registered enrollment target is 20 participants, below the 136-participant average among 30 other Melanoma (Skin) trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00002952, a Phase 1 study of Melanoma (Skin), has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Vaccines made from a tumor antigen gene may make the body build an immune response to kill tumor cells. Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cell to kill melanoma cells. Combining vaccine therapy with interleukin-12 may kill more melanoma cells. PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy plus interleukin-12 in treating patients who have metastatic melanoma.
Conditions Studied
Interventions
- BIOLOGICAL recombinant interleukin-12
- BIOLOGICAL MART-1 antigen
- BIOLOGICAL recombinant MAGE-3.1 antigen
Study Locations (1)
Illinois
- University of Chicago Cancer Research Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 1997-01 |
| Est. Completion | 2002-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002952
The ClinicalTrials.gov registry entry for NCT00002952 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 136-participant average among 30 other Melanoma (Skin) trials with a reported enrollment target (85% lower). The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Melanoma (Skin) appearing as the primary indexed condition, and to 3 interventions - of which recombinant interleukin-12 is the first listed.
NCT00002952 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT00002952 about?
NCT00002952 is a clinical study titled "Vaccine Therapy and Interleukin-12 in Treating Patients With Metastatic Melanoma". RATIONALE: Vaccines made from a tumor antigen gene may make the body build an immune response to kill tumor cells. Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cell to kill melanoma cells. Combining vaccine therapy with interleukin...
What is the current status of trial NCT00002952?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 1997-01. Estimated completion is 2002-11.
What conditions does trial NCT00002952 study?
This clinical trial studies the following conditions: Melanoma (Skin).
What interventions are being tested in trial NCT00002952?
The interventions under investigation include: recombinant interleukin-12 (BIOLOGICAL), MART-1 antigen (BIOLOGICAL), recombinant MAGE-3.1 antigen (BIOLOGICAL).
Who is sponsoring clinical trial NCT00002952?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002952 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma (Skin)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
RECRUITING · Phase 1
-
Vaccine Therapy in Treating Patients With Metastatic Melanoma
COMPLETED · Phase 1
-
Vaccine Therapy in Treating Patients With Melanoma
COMPLETED · Phase 1
-
Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma
COMPLETED · Phase 1
-
Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma
COMPLETED · Phase 1
-
Biological Therapy in Treating Patients With Metastatic Melanoma
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.